Market Access/ News/ News FDA panel turns down Acadia’s Nuplazid for Alzheimer’s psychosis Phil Taylor Acadia Pharmaceuticals, Alzheimer's disease, fda, Nuplazid, psychosis 0 Comment Acadia Pharma’s attempts to extend the indications of its Nuplazid drug in the US to include Alzheimer’s disease-related Share X FDA panel turns down Acadia’s Nuplazid for Alzheimer’s psychosis https://pharmaphorum.com/news/fda-panel-turns-down-acadias-nuplazid-for-alzheimers-psychosis/
Market Access/ News/ News Acadia puts blame on FDA as Nuplazid rejected for dementia George Underwood Acadia, dementia, fda, Nuplazid, psychosis 0 Comment Acadia Pharmaceuticals is butting heads with US regulators again, this time over the FDA’s decision to reject its Share X Acadia puts blame on FDA as Nuplazid rejected for dementia https://pharmaphorum.com/news/acadia-blame-fda-nuplazid-rejected-dementia/
Acadia Pharmaceuticals, Alzheimer's disease, fda, Nuplazid, psychosis
0 Comment
